CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. (16th October 2018)

• Record Type: Journal Article
• Authors: Lin, Han-Wei; Fu, Chi-Feng; Chang, Ming-Cheng; Lu, Tzu-Pin; Lin, Hsiu-Ping; Chiang, Ying-Cheng; Chen, Chi-An; Cheng, Wen-Fang
• Is Part Of: Epigenomics. Volume 10:Number 11(2018)
• Page Start: 1397
• Page End: 1413
• Publication Date: 2018-10-16
• Subjects: advanced stage -- capillary electrophoresis -- CDH1 -- DLEC1 -- epithelial ovarian cancer -- gene methylation -- methylation-specific PCR -- prognostic biomarker -- SFRP5 -- TCGA dataset; Epigenesis -- Periodicals; Genomics -- Periodicals; Chromatin -- Periodicals; DNA -- Periodicals; 572.87
• DOI: 10.2217/epi-2018-0035
• Languages: English
• ISSNs: 1750-1911

Abstract

Aim: To investigate the CDH1, DLEC1 and SFRP5 gene methylation panel for advanced epithelial ovarian carcinoma (EOC).Materials & methods: One hundred and seventy-seven advanced EOC specimens were evaluated by methylation-specific PCR. We also used The Cancer Genome Atlas dataset to evaluate the panel.Results: The presence of two or more methylated genes was significant in recurrence (hazard ratio [HR]: 1.91 [1.33–2.76]; p = 0.002) and death (HR: 1.96 [1.26–3.06]; p = 0.006) in our cohort. In The Cancer Genome Atlas dataset, the presence of two or three methylated genes was significant in death (HR: 1.59 [1.15–2.18]; p = 0.0047) and close to the significance level in recurrence (HR: 1.37 [0.99–1.88]; p = 0.058).Conclusion: The CDH1, DLEC1 and SFRP5 methylation panel is a potential prognostic biomarker for advanced EOC. Graphical abstract: